| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC22A9 |
| Uniprot No | Q8IVM8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-238 aa |
| 活性数据 | MAFQDLLGHAGDLWRFQILQTVFLSIFAVATYLHFMLENFTAFIPGHRCWVHILDNDTVSDNDTGALSQDALLRISIPLDSNMRPEKCRRFVHPQWQLLHLNGTFPNTSDADMEPCVDGWVYDRISFSSTIVTEWDLVCDSQSLTSVAKFVFMAGMMVGGILGGHLSDSSRVGNTQIPGHGNYIGNVPFWYCIYDPGRPGFCHSRLAYPPAGGVCTILCDLSDLKLAARVCSVAHYQQ |
| 分子量 | 52.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于重组人SLC22A9(OAT7)蛋白的研究文献摘要，涵盖功能、病理机制及结构解析方向：
---
1. **文献名称**: *"Functional characterization of recombinant human OAT7 (SLC22A9) as a transporter of steroid sulfates"*
**作者**: Miyata et al. (2019)
**摘要**: 首次成功在HEK293细胞中表达重组人OAT7蛋白，证实其特异性介导硫酸化类固醇(如脱氢表雄酮硫酸盐)的钠非依赖性转运。实验证明OAT7在肝细胞基底膜表达，可能参与内源性物质的肝胆循环。
2. **文献名称**: *"SLC22A9 gene polymorphism modulates uric acid transport in hepatic cells and associates with NAFLD progression"*
**作者**: Wang et al. (2021)
**摘要**: 通过CRISPR/Cas9构建SLC22A9敲除肝细胞模型，发现OAT7通过调节尿酸外排影响细胞内氧化应激水平。全基因组关联分析表明，rs117456052 SNP与亚洲人群非酒精性脂肪肝(NAFLD)纤维化程度显著相关。
3. **文献名称**: *"Cryo-EM structure of human OAT7 reveals a conserved binding pocket for organic anion recognition"*
**作者**: Liu et al. (2022)
**摘要**: 利用冷冻电镜技术解析OAT7蛋白的3.2Å三维结构，揭示其跨膜域形成由TM1/TM6螺旋构成的疏水结合口袋，关键残基Arg37和Tyr333通过电荷相互作用识别阴离子配体，为靶向药物设计提供结构基础。
---
**备注**：若需获取全文链接或具体实验方法细节，可进一步通过PubMed或DOI号检索。
The SLC22A9 protein, also known as organic anion transporter 4 (OAT4) or URAT1. belongs to the solute carrier family 22 (SLC22), a group of membrane transporters involved in the movement of endogenous and exogenous organic anions across cellular membranes. Primarily expressed in the kidney, liver, and reproductive tissues, SLC22A9 facilitates the uptake of urate, a key intermediate in purine metabolism, and other organic anions like estrone sulfate. It plays a critical role in renal urate reabsorption, making it a therapeutic target for hyperuricemia and gout. Structurally, it comprises 12 transmembrane domains with intracellular N- and C-termini, typical of SLC transporters.
Research highlights its involvement in drug disposition, particularly in nephrotoxicity and drug-drug interactions. For instance, SLC22A9 mediates the transport of diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), and antivirals, influencing their pharmacokinetics. Genetic polymorphisms in SLC22A9 have been linked to interindividual variability in urate levels and drug responses, underscoring its pharmacogenomic relevance. Recombinant SLC22A9 protein, produced via heterologous expression systems (e.g., HEK293 cells), is widely used in vitro to study substrate specificity, inhibition mechanisms, and structure-function relationships. Its role in hormonal regulation, particularly in steroid sulfate transport, also connects it to endocrine signaling pathways. Understanding SLC22A9's functionality advances precision medicine approaches for metabolic and renal disorders.
×
